Combination therapy for autoimmune encephalitis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests if combining two medications (a B-cell depleting drug and daratumumab) can help people with autoimmune encephalitis who haven't improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older
- You have been diagnosed with autoimmune encephalitis related to a surface protein on nerve cells
- You have already tried at least one standard treatment (like high-dose steroids, IVIG, plasma exchange, or efgartigimod) without enough improvement
- Your current symptoms are moderate to severe, based on a disability score of 3 or higher
- You do not have serious active infections, certain liver or blood problems, or a history of severe allergies to study drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
This study tests whether an experimental treatment using tiny particles from stem cells (called exosomes) given through the nose can help people with autoimmune encephalitis. It is for adults who were recently diagnosed and have specific antibodies.
This Phase 2 study tests whether bortezomib can improve outcomes and safety in adults with severe autoimmune encephalitis. It focuses on people whose condition is confirmed by brain-related autoantibodies and who have already received rituximab.
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
This Phase 2 study tests inebilizumab in people with NMDA receptor encephalitis, an immune-related brain condition. It looks to see if adding this treatment after starting steroids (and possibly other first treatments) improves recovery and safety.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Anti-N-Methyl-D-Aspartate Receptor Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.